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Abstract
Background: To describe the protocol for developing a national inherited retinal disease (IRD) registry in Iran and present its initial 
report. 
Methods: This community-based participatory research was approved by the Ministry of Health and Medical Education of Iran in 
2016. To provide the minimum data set (MDS), several focus group meetings were held. The final MDS was handed over to an 
engineering team to develop a web-based software. In the pilot phase, the software was set up in two referral centers in Iran. Final 
IRD diagnosis was made based on clinical manifestations and genetic findings. Ultimately, patient registration was done based on 
all clinical and non-clinical manifestations. 
Results: Initially, a total of 151 data elements were approved with Delphi technique. The registry software went live at www.
IRDReg.org based on DHIS2 open source license agreement since February 2016. So far, a total of 1001 patients have been 
registered with a mean age of 32.41±15.60 years (range, 3 months to 74 years). The majority of the registered patients had retinitis 
pigmentosa (42%, 95% CI: 38.9% to 45%). Genetic testing was done for approximately 20% of the registered individuals.
Conclusion: Our study shows successful web-based software design and data collection as a proof of concept for the first IRD 
registry in Iran. Multicenter integration of the IRD registry in medical centers throughout the country is well underway as planned. 
These data will assist researchers to rapidly access information about the distribution and genetic patterns of this disease.
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Inherited retinal diseases (IRDs), the most prevalent 
hereditary and untreatable cause of visual impairment, are 
a group of rare ocular disorders associated with progressive 
visual compromise.1,2 While IRDs follow Mendelian 
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(RP) as the most common type of IRD is estimated to be 1 
per 4000 individuals all around the world.4-6 
According to the definition presented by the National 
Committee on Vital and Health Statistics, a patient or 
a disease registry is an organized system for collection, 
storage, retrieval, analysis, and dissemination of 
information being widely applied in medicine and public 
health domain.7,8 Registries are essential tools for providing 
information about the prevalence and natural history 
of a particular type of disease, discovering associated 
environmental and genetic factors, and prognosis related to 
different therapeutic approaches.8-11 From administrative 
perspectives, patient and disease registries are efficient 
tools in improving health outcomes as well as reducing 
treatment costs. In addition, they may become useful in 
providing clinical guidelines and recruiting patients for 
clinical trial studies.8-13 
The number, size and scope of patient registries 
in the field of ophthalmology have been gradually 
growing all around the world during the last decade.14 
A comprehensive review by Tan et al showed that a total 
of 85 clinical registries have been established in various 
fields of ophthalmology, including blindness or low vision 
(n = 19), corneal transplantation (n = 10), glaucoma (n = 
10), cataract or refractive surgery (n = 8), retinoblastoma 
(n = 7), endophthalmitis or uveitis (n = 6), ocular 
trauma (n = 6), age-related macular degeneration (n = 
5), microphthalmia or congenital ocular anomalies (n = 
4), diabetic retinopathy (n = 2) and retinal detachment 
or macular hole (n = 2).14 Additionally, there are several 
clinical registries focusing on IRDs or RP throughout the 
world.2,14-17 A well-organized disease identification based 
on genotyping and phenotyping characteristics of each 
type of IRD provides a comprehensive dataset based on 
actual data focusing on geographical features that can be 
crucial for gene therapy in future.3 
The complete set of inherited and environmental factors 
contributing to IRDs in the Iranian population has not 
been systematically cataloged due to lack of access to 
standardized information resources. A national patient 
registry for IRDs has the potential to identify disease 
prevalence along with genetic inheritance patterns, disease-
causing genes and mutations as well as clinical outcomes 
and to set a framework for applying possible therapeutic 
approaches.8-13 The drive to learn more about these aspects 
in our patient population resulted in the development 
of our first national registry for IRDs with the research 
protocol described below and the initial results of the pilot 
phase.
Material and Methods
This is a community-based participatory study which 
was performed in two referral eye centers including 
Labbafinejad Medical Center located in the capital city, 
Tehran, and Alzahra Eye hospital, located in southeast 
of Iran, city of Zahedan. The pilot discovery phase was 
conducted to identify possible barriers for implementation 
of the national phase in multiple cities with various 
geographical characteristics. The following steps describe 
how this registry was developed and implemented.
Objectives for Developing an Iranian Registry for IRDs 
• To determine the prevalence and incidence of retinal 
dystrophies in Iran based on patient age groups, 
ethnicities, and demographics,
• To identify the genetic landscape and inheritance 
patterns of IRDs among Iranian populations,
• To provide pooled data based on real clinical and 
genetic characteristics and formulate the best 
therapeutic planning in future,
• To develop a database to facilitate international data 
exchange and research collaborations. 
 
Review of other IRD Registries
There are several global and national registries focusing 
on IRDs or RP throughout the world.2,14-17 My Retina 
TrackerTM is a global online registry, created and supported 
by the Foundation Fighting Blindness (FFB), containing 
all medical records of affected individuals as well as 
their unaffected relatives.15 This registry can be accessed 
by patients, researchers, and clinicians. Other national 
registries include: Spanish patient registry of hereditary 
retinal dystrophy, French registry of patients affected by 
Leber congenital amaurosis and retinitis pigmentosa, 
Swedish database on Usher syndrome, Danish Retinitis 
Pigmentosa Registry, Dutch RD5000 database 
(RD5000db), and Australian Inherited Retinal Disease 
Registry and DNA Bank.2,14,16 
Case Definition and Recruitment in our National IRD 
Registry 
Patients from all age groups were recruited sequentially 
based on the general announcement via social media and 
patient support associations. An initial registration was 
performed for Iranian individuals who were diagnosed 
with IRD based on clinical and paraclinical findings by 
a board certified retina specialist. The IRD diagnosis 
was later confirmed by genetic testing in some of the 
registrants. 
Data Elements
In this phase, a minimum data set (MDS) for the IRD 
registry was developed in the following three steps 
including literature review, classification of data elements, 
and final approval by Delphi technique. 
An initial data set was provided based on a clinical form 
being used in the clinic of ophthalmology at Labbafinejad 
Medical Center, Tehran, Iran. The dataset was further 
completed based on other IRDs registries worldwide. 
We completed several interviews with academic retina 
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specialists to verify that the dataset is accurate in practice. 
Subsequently, the data set resulting from interviews 
was presented to the Delphi panelists. In the last step, 
the final MDS was validated using two rounds of Delphi 
technique. For this purpose, subject matter experts 
were invited from different domains including board 
certificated retina specialists (n = 5), epidemiologists (n = 
2), geneticists (n = 2) and a visual science specialist (n = 1). 
A questionnaire was presented to the panel participants in 
order to determine the importance of each data element 
using the 5- Likert scale (from 1-lowest to 5-highest), to 
display information (numeric, text, multiple choice, and 
binary), and the necessity of data recording (required or 
optional). All participants were asked to insert additional 
suggestions for each data element or suggest another one 
if necessary. 
Inclusion criteria of data elements in the MDS were based 
on the level of agreement resulting from the participants’ 
response in Delphi rounds. Elements with a score of 4 or 5 
by at least 70% of participants were included in the MDS, 
while elements with a score of 1 or 2 from at least 70% of 
participants were excluded. Afterwards, the remaining data 
elements based on participants’ suggestions were discussed 
in the second round of Delphi technique. 
In this step, the first questionnaire was revised based on 
the feedback received from participants with no chance for 
additional suggestions, and it was presented to the second 
Delphi round. Initially, the results obtained from the first 
round were presented to the participants and they were 
asked to assign a scoring number to each data element as 
had been previously performed. Like the first round, data 
elements with 70% agreement that scored 4 or 5 were 
included in the final MDS and the remaining elements 
were disregarded.
Data Collection and Quality Assurance
The quality control phase contained three steps including 
data collection, data entry, and final registration 
confirming the IRD diagnosis. For this purpose, a standard 
administrative protocol was developed and approved by 
the steering committee members. All examination tools 
including low vision chart as well as the procedure guideline 
for patient examination were standardized for cohesive 
data collection. Furthermore, a software was developed so 
that the validation rules prevent non-standard data entry. 
Clinical staffs were also trained to document patients’ data 
either online or offline. The medical history of each patient 
was also recorded carefully for accurate final diagnosis. 
Genetic testing was done for some of the registered cases 
to verify diagnosis. Furthermore, family members of some 
patients were recruited to better characterize genotype-
phenotype correlations. 
Governance and Steering Committee 
The work for this national registry was approved and funded 
by the Iranian Ministry of Health and Medical Education 
in 2016. We established a national steering committee 
for managing eight sub-committees including health 
terminology and coding, financial and administrative, data 
entry, quality control and evaluation, statistical analysis 
and epidemiology, information technology, scientific 
and research, as well as documentation and website 
update group (Figure 1). Meetings were held annually to 
investigate and resolve barriers as well as making decisions 
about the future of the program. 
Biobank and Biological Samples
Blood samples were collected from all consenting 
participants to create a DNA biobank for genetic studies. 
Genomic data from DNA was extracted from peripheral 
blood leukocytes using the standard salting out method. 
A unique ID for each sample was used for the DNA 
collection tubes. We aimed to create a DNA biobank 
linked to phenotypic data derived from a web-based 
registry software in order to increase our understanding 
about causative genes/mutations and genotype-phenotype 
correlations among the Iranian IRD affected patients. 
This knowledge base could potentially help with genetic 
counseling of the affected families and planning for the 
future genetic-based therapeutic approaches.
Genetic Testing 
We analyzed 195 patients from 122 Iranian families, 
with no relationship to each other, who participated 
in our IRD registry using two sequencing techniques. 
These techniques include targeted sequencing of 108 
IRD-associated genes (160 patients from 92 unrelated 
families) and whole exome sequencing (35 patients from 
30 unrelated families) in collaboration with two academic 
institutes from the Netherlands and Germany, respectively.
A cost-effective targeted sequencing based on molecular 
inversion probes (MIPs) was used to sequence the coding 
regions of 108 non-syndromic IRD-associated genes 
in probands of 92 unrelated families. For the 30 other 
families, exome enrichment (Nextera Rapid Capture, 
Illumina) was carried out by hybridization of all coding 
exons and flanking intron sequences and paired-end 2x76 
bp sequencing on the NextSeq 500 sequencer (Illumina) 
using the NextSeq Reagent Kit v2. Sequence alignment and 
variant calling were performed against human reference 
genome UCSC NCBI37/hg19 by CASAVA software 
(Illumina). Additionally, wANNOVAR (http://wannovar.
wglab.org/) and ENSEMBL (http://asia.ensembl.org/
info/docs/tools/index.html) tools were used for variant 
detection. Inherited retinal dystrophies are heterogeneous 
genetic disorders. Variants in more than 300 genes have 
been described to cause IRDs (RetNet; Retinal Information 
Network, https://sph.uth.tmc.edu/retnet/). Variations 
in all identified IRD genes were considered for genetic 
analysis in our research. Subsequently, candidate variations 
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were selected by removing SNPs with a MAF of > 0.01 
in the dbSNP database (https://www.ncbi.nlm.nih.gov/
snp/), the 1000 Genomes databases (www.1000genomes.
org), the NHLBI Exome Sequencing Project (http://evs.
gs.washington.edu/EVS/), and the Exome Aggregation 
Consortium database (http://exac.broadinstitute.org/). 
At first, we searched for the already known pathogenic 
mutations in the variations list. In the absence of 
known pathogenic mutations, the candidate variants 
were screened for segregation in the pedigrees by Sanger 
sequencing of the DNA obtained from existing family 
members. For the nucleotide changes that were novel or 
of unknown clinical significance, in silico bioinformatics 
tools were used to predict and score the deleterious effects 
of the identified variants on the protein product. Cases 
with likely pathogenic variant(s) were flagged when the 
affected gene matched the described phenotype and the 
detected variant(s) segregated in the family.
Software Development
The steering committee selected an expert engineering 
team affiliated to Amir Kabir University of Technology 
in Tehran, Iran for software development as well as a 
private vendor who contributed to software support and 
maintenance. The steering committee members had 
several business analysis meetings with the company 
analysts and developers who were medical informaticists 
and specialists in health information technology. In these 
meetings, the functionalities of the software, data forms, 
users’ accessibilities, validation rules and pre-defined 
reports were specified. The Iran IRD registry software 
is a web-based software (http://irdreg.org) that has been 
developed based on an open software license (DHIS2) 
utilizing PostgreSQL and Java. 
The developed software covers several informational 
sections such as patient demographic and hereditary 
characteristics, history of systemic and ocular diseases, 
biobank data, visual and ophthalmic findings, paraclinical 
information, genetic data and final IRD diagnosis in an 
electronic case report format. Several validation rules were 
designed to ensure data validity, format, and completeness. 
Additionally, the final IRD diagnosis concepts were verified 
Figure 1. Flowchart of the Iranian National Registry of Inherited Retinal Dystrophy (IRD) Diseases.
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by available online terminology resources such as Unified 
Medical Language System (UMLS), Online Mendelian 
Inheritance in Man (OMIM), International Classification 
of Diseases (ICD-11), Systematized Nomenclature of 
Medicine (SNOMED-CT) and Orphanet Rare Disease 
Ontology (ORDO). A screenshot of the IRDReg software 
is illustrated in Figure 2.
For security and data accessibility, we defined several 
organizational units for our collaborative centers all around 
the country and designated specific users for each unit. 
Every user could only have access to his/her profile’s data. 
The software is centrally maintained by the Ophthalmic 
Research Center affiliated to Shahid Beheshti University 
of Medical Sciences. In this center, the national principal 
investigator and executive director of the project have 
access to all data. 
Statistical Analysis
To describe data, we used mean, standard deviation, 
median and interquartile range, frequency and percentage. 
Clopper-Pearson 95% confidence interval was used to 
present precision of percentage estimates. All statistical 
analyses were performed using the STATA software 
(StataCorp. 2017. Stata Statistical Software: Release 15. 
College Station, TX: StataCorp LLC).
Results
The IRD registry was developed according to the above-
mentioned steps in two qualitative and quantitative study 
phases. The registry protocol was also listed and disclosed 
on: www.clinicaltrial.gov website (registration number 
NCT04131400). The workflow from patient recruitment 
to patient registration is presented in Figure 1. 
Minimum Data Set 
Based on the comprehensive review of literature, clinical 
forms from other registries, and reference textbooks, a 
total of 160 preliminary data elements were identified. 
This list was verified by individual interviews with each 
of the academic retina specialists and reduced to 145 
data elements in eight categories, including demographic 
information, hereditary characteristics, history of systemic 
Figure 2. A Screenshot of the IRDReg Software for Data Recording of Patients Suffering from Inherited Retinal Dystrophy.
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and ocular status, biobank data, visual examination, 
ophthalmic findings, paraclinical data and genetic 
findings. The final list, however, contains a total of 151 
data elements in the eight above-mentioned categories 
that were approved and validated by two rounds of the 
Delphi technique (some of data elements are presented 
in Supplementary file 1). Figure 3 presents a flowchart 
showing the process by which the elements were included 
in the final dataset.
Demographic Characteristics
A summary of the demographic characteristics of the 
registered patients are presented in Table 1. A total of 
1001 IRD patients with a mean age of 32.41 ± 15.60 
years (range, 3 months to 74 years) were registered in 
our database.  Clinical examination of 555 male subjects 
(56%) and 446 female subjects (44%) were recorded. The 
majority of the IRD patients (26.7%) were in the third 
decade of their lives, while only 10 patients were aged one 
year or younger. Furthermore, parental consanguinity was 
recorded in 76% of the registered patients (first degree 
relationship was observed in 66%) and 58% of our cases 
had a positive family history of at least two affected 
individuals in their family or relatives.
The majority of registered patients were of Persian 
ethnicity (51%). Additionally, 35% of the registered 
patients were employed in different occupations which 
were in proportion to their visual ability, while 13% of 
them were jobless due to their visual impairment. The 
majority of our registered patients (57%) had a low level 
of education and 3% of them were illiterate due to the 
early onset of severe visual impairment. 
Figure 3. Data Validation Flowchart for Minimum Data Set (MDS) Determination.
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Table 1. Demographic Characteristics of the Registered Patients in the Iranian 
IRD Registry
Characteristics No. (%) Mean ± SD Median (Range)
Age (years) — 32.41 ± 15.60 32.0 (0.30 to 74.0)
95% CI
Lower (%) Upper (%)
Gender 
Male 555 (55.4) 52.5 58.6
Female 446 (44.6) 41.4 47.5
Age categories (years)
[Birth–1] 10 (1.0) 0.5 1.8
(1–11] 99 (9.9) 8.2 11.9
(11–21] 136 (13.6) 11.6 15.9
(21–31] 234 (23.5) 20.9 26.2
(31–41] 266 (26.7) 24.0 29.5
(41–51] 125 (12.5) 10.6 14.7
(51–61] 84 (8.4) 6.8 10.3
> 61 43 (4.3) 3.2 5.7
Parental consanguinity 
No 195 (20.4) 18.0 23.1
Yes (first degree) 500 (52.4) 49.2 55.6
Yes (second degree) 259 (27.1) 24.4 30.0
Positive family history 
No 375 (39.0) 36.0 42.1
Yes 586 (61.0) 57.9 64.0
History of systemic diseases 
No 662 (67.6) 64.6 70.4
Yes 318 (32.4) 29.6 35.4
Iranian ethnicity 
Fars 419 (51.2) 47.8 54.6
Turk 196 (24.0) 21.1 27.0
Kurd 56 (6.8) 5.3 8.7
Lur 43 (5.3) 3.9 6.9
Gilak 13 (1.6) 0.9 2.6
Mazani 18 (2.2) 1.4 3.4
Baluch 51 (6.2) 4.7 8.0
Tat 6 (0.7) 0.3 1.5
Arab 9 (1.1) 0.5 2.0
Others 7 (0.9) 0.4 1.7
Occupation 
Employed 345 (35.1) 32.2 38.2
Jobless 129 (13.1) 11.1 15.4
Housekeeper 165 (16.8) 14.6 19.2
Disabled 10 (1.0) 0.5 1.8
Student 217 (22.1) 19.6 24.8
Retired 59 (6.0) 4.6 7.6
Pre-school 51 (5.2) 3.9 6.7
Mentally retarded 6 (0.6) 0.3 1.3
Level of education
Illiterate 34 (3.5) 2.5 4.8
Preschool 44 (4.6) 3.4 6.0
Unable to learn 2 (0.2) 0.0 0.7
Under diploma 327 (33.9) 30.9 36.9
Diploma 246 (25.5) 22.8 28.3
Bachelor or master 292 (30.2) 27.4 33.2
PhD or higher 21 (2.2) 1.4 3.2
Clinical Findings
The mean age of onset of patients’ symptoms or from 
reports by their care-givers was 15.6 ± 13.6 years (median: 
12, range, birth to 70 years). An average of 1.34 ± 
1.06 (median: 0.90, inter-quartile range: 0.40 to 2.80) 
LogMAR best corrected visual acuity (BCVA; range, -0.12 
to 3.10) was recorded for the registered IRD patients. 
Mild visual impairment presenting with visual acuity 
(PGVA) between 0.3 to 0.48 LogMAR in the better eye 
according to the International Classification of Diseases 
reported by the World Health Organization (WHO)18 was 
detected in 8.5% of the patients; while 31.9% and 37.7% 
of our patients had low vision (range of PGVA, 0.48 to 
1.30 LogMAR) or were blind (PGVA worse than 1.30 
LogMAR), respectively. 
In addition, color vision deficiency (defined as detection 
of 8 plates or less from a total of 38 plates of the Ishihara 
color vision test)19 was identified in 30% of our patients. 
The mean spherical equivalent of refractive errors was 
-1.36 ± 3.96 diopters (D; range, -17.75 myopia to +11.75 
hyperopia) with a high percentage of myopia (44.5%, 
Table 2). 
Figure 4 illustrates the percentage of IRD diagnoses in 
the eight general categories according to the functional 
and genetic entities. The majority of the registered patients 
had retinitis pigmentosa (42%, 95% CI: 38.9% to 45%) 
which was classified as the most prevalent subtype of diffuse 
photoreceptor dystrophy. Leber’s congenital amaurosis 
(15%, 95% CI: 12.9% to 17.3%) and cone-rod dystrophy 
(11.4%, 95% CI: 9.5% to 13.5%) were diagnosed as the 
second and the third common diagnoses among the study 
population. 
Genetic Report
To date, we have DNA samples from the majority of the 
registered patients in our biobank from 843 unrelated 
families. About 15% of these families (122 from 843 
families) and 20% of all the registered patients (195 from 
1001 patients) have been genetically analyzed and the 
genetic reports have been reported back to the participants. 
The causative mutations in about 72% of the investigated 
families were identified in the known IRDs causing genes 
and about 80% of the identified variants were novel as 
IRD-causing mutations. Final diagnosis based on retinal 
imaging and clinical diagnosis was confirmed by analysis 
of all genetically studied cases. 
Discussion
The IRD registry developed by us is the first national 
registry established for eye diseases in Iran. In the 
pilot phase, two medical centers located at different 
geographical zones with diverse socioeconomic conditions 
were selected; the capital and one of cities in the southeast 
of Iran were selected in order to identify possible obstacles 
in establishing the registry. 
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The IRD registry application software was developed 
based on open access DHIS2, which is one of the main 
health information systems (HIS) for data collection in 
disease registries.20 The registry outputs are frequently used 
in decision making in health care systems.20,21 Based on a 
recent review conducted by Dehnavieh et al,21 DHIS2 has 
been used in patient registries at different levels of HIS 
in 46 countries. Additionally, electronic health records 
can not only be beneficial for individual research studies 
but can also facilitates scientific collaboration with other 
international research centers throughout the world.22 
Electronic health information resulting from patient 
registries or other healthcare data sources are considered 
Table 2. Clinical Characteristics of the Registered Patients in the Iranian IRD 
Registry
Clinical Characteristics No. (%) Mean ± SD
Median 
(Range)
Age of onset (years) —
15.58 ± 
13.59
12.0 (0.08 to 
70.0)
BCVA (LogMAR) — 1.34 ± 1.06
0.90 (-0.12 to 
3.10)
SE (D) — -1.36 ± 3.96
-1.0 (-17.75 to 
11.88)
95% CI
Lower (%) Upper (%)
Age of onset categories 
[Birth–1] 156 (16.1) 13.9 18.5
(1–11] 296 (30.5) 27.6 33.4
(11–21] 252 (26.0) 23.3 28.8
(21–31] 125 (12.9) 10.9 15.1
(31–41] 94 (9.7) 7.9 11.7
(41–51] 36 (3.7) 2.7 5.0





Normal VA (≤ 0.30) 185 (19.2) 16.8 21.8
Mild VI (0.30–0.48] 82 (8.5) 6.9 10.4
Low Vision (0.48–1.0] 266 (27.6) 24.9 30.5
Low Vision (1.0–1.30] 53 (5.5) 4.2 7.1
Blindness (1.30–1.78] 61 (6.3) 4.9 8.0
Blindness (1.8, 3.0) 296 (30.7) 27.9 33.7
Blindness (NLP = 3.1) 20 (2.1) 1.3 3.1
Color vision (%)
Normal 120 (13.0) 11.0 15.3
Deficiency 298 (32.4) 29.4 35.4
N/A 503 (54.6) 51.4 57.8
RE categories (D)
High Myopia (≤-5.00) 140 (14.7) 12.5 17.0
Myopia (-5.00 to -0.50] 425 (44.5) 41.4 47.7
Emmetropia (-0.50 to +0.50] 152 (15.9) 13.7 18.4
Hyperopia (+0.50 to 141 (14.8) 12.6 17.1
High hyperopia (>+3.00) 96 (10.1) 8.3 12.1
IRD, inherited retinal dystrophy; BCVA, best corrected visual acuity; LogMAR, 
logarithm minimum angle of resolution; SE, spherical equivalent; RE, 
refractive error; NLP, no light perception; D, diopter; SD, standard deviation; 
VI, visual impairment; CI, confidence interval; N/A, not applicable.
Figure 4. Percentage of Different Types of Inherited Retinal Dystrophy 
among the Registered Patients.
valuable data sources that are essential in any national HIS 
system for identifying the natural history of diseases as 
well as the common therapeutic plans.23 Therefore, linkage 
between various data (and ultimately knowledge) objects is 
one of the fundamental considerations in registry database 
design. In the IRD registry, the personal profile of each 
patient was identified by his/her 10-digit standard national 
code which provides the possibility of data linkage with 
other sources of patient information in EHRs in Iran such 
as SEPAS and SIB national health projects. 
Furthermore, utilizing five standard terminology systems 
with respect to the anatomical and genetic characteristics 
of the IRD concepts increases our registry validation in 
data recording and provides the possibility of scientific 
collaboration with higher accuracy. 
To our knowledge, there are several global or national 
patient registries which have been established for IRDs 
throughout the world.2,14-17 The most prominent registry 
is My Retina TrackerTM which was launched by the FFB to 
register patients around the world.15 The blood samples of 
the unaffected relatives of patients with IRDs were kept in 
the biobank of My Retina TrackerTM, which is a standard 
practice that we have also integrated into our IRD registry 
workflow. In My Retina TrackerTM, patients can access 
their data. However, this feature was not considered in 
our registry to avoid sample selection bias. The steering 
committee of our registry believed that self-registration 
by the patients induces selection bias, since only literate 
patients, those with accessibility to an internet connection, 
and patients who were aware of their disease conditions 
would have an opportunity to register. With respect to the 
frequency of IRD subtypes, our reports were compatible 
with My Retina TrackerTM report showing about half of 
the registered patients with retinitis pigmentosa. Patients 
with a diagnosis of age-related macular degeneration 
were also registered in My Retina TrackerTM which is not 
classified as IRDs. 
The Danish Retinitis Pigmentosa Registry is the national 
registry for IRD diseases in Denmark.2 In this registry, 
patient diagnosis is performed based on clinical findings via 
fundus color photography and electrophysiological tests. 
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Three diagnostic proceedings including pedigree drawing, 
electroretinographic, and genetic testing are recommended 
for definite diagnosis of IRD, especially in the pediatric 
population.1 Comprehensive clinical examinations and 
retinal imaging were performed to determine the IRD 
diagnosis in our IRD registry. Additionally, genetic testing 
is another supplementary diagnostic tool which has been 
conducted for registered patients in our registry and will be 
completed in the future. Syndromic retinitis pigmentosa 
was observed in 28% of the registered patients in Danish 
Retinitis Pigmentosa Registry, while it was seen in only 
8.89% of our registered patients. 
Our review of the literature shows the frequency of 
IRDs, as well as the inheritance pattern and genetic 
characteristics among the affected Iranian population 
have not been previously reported; therefore, this registry 
would be helpful in identifying eligible patients who 
may give consent to participating in clinical trials. It can 
also be beneficial for providing gene- and variant-level 
information for the development of a novel gene therapy. 
Establishment of a genetic diagnosis in patients with 
IRD diseases is essential to guide appropriate genetic 
counseling. Furthermore, recognition of the inheritance 
pattern is crucial for calculating risk in family planning 
situations in individuals with a positive family history.24 
This feature was also considered in the design of our 
registry.
Our clinical findings show that nearly one-third of our 
registered patients (30.5%) have noticed symptoms such 
as nyctalopia, hemeralopia, photophobia, color vision 
deficiency, restricted visual field, and the prolonged latency 
of light and dark adaptation in the first decade of life. The 
early onset of disease manifestation correlates with severe 
visual impairment in the majority of our patients (30.7%) 
who have been categorized as blind based on the WHO 
classification.18 
Furthermore, the majority of our registered patients 
(74.43%) were under 40 years of age who are expected 
to benefit from educational tools and occupation 
opportunities. Low levels of education and high percentage 
of unemployment among our patients can be attributed 
to the reduced vision and lack of appropriate ability for 
learning and working. 
Due to the diversity of the geographical features of Iran 
and difficulties for referring patients to the centers that are 
far from their residential areas, we intend to expand the 
project in the provinces without any registration centers. 
This will also enhance our registration coverage. 
The current study, as a pilot, establishes a database 
registry for IRDs in Iran with the following lessons learned: 
To avoid selection bias, access to data entry was given only 
to one retina specialist as the focal point in each academic 
center. To enhance the validity of the date, no information 
extraction from other EMR sources was permitted. Data 
linkage among the affected individuals related to one 
genetic pedigree was guaranteed by assignment of a prefix to 
the IRD codes as a unique identifier. Also, the attachment 
of the affected patients to the main proband was expected 
in the software design. We avoided duplication in data 
entry through automated verification of the patients’ 
national code. Lastly, to anticipate occasional internet 
connectivity disruption, both offline and online modules 
were provisioned for data entry, while the software was 
designed as a mobile application for better accessibility. 
One of the limitations in data collection was relying 
on patient’s self-report for some of the data elements 
such as the disease onset age. Therefore, cross-validation 
of patients’ response with clinical records was performed 
to increase data validity. Data collection was incomplete 
for some of the data elements; however, the missing rate 
was generally under 8% which could be in the acceptable 
range.
In conclusion, our study shows a successful web-based 
software design and data collection as a proof of concept 
for the first Iranian IRD registry. Therefore, we are 
currently in the process of planning to extend this study 
and IRD application to other medical centers throughout 
the country. These data will assist researchers to rapidly 
access structured information about the distribution of 
the patterns of genetically  heterogeneous retinal diseases 
in Iran for identification of preventive and therapeutic 
measures in near future.
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